Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Long-Term Investments (2016 - 2022)

Assembly Biosciences has reported Long-Term Investments over the past 6 years, most recently at $11.7 million for Q4 2022.

  • Quarterly results put Long-Term Investments at $11.7 million for Q4 2022, down 58.02% from a year ago — trailing twelve months through Dec 2022 was $11.7 million (down 58.02% YoY), and the annual figure for FY2022 was $11.7 million, down 58.02%.
  • Long-Term Investments for Q4 2022 was $11.7 million at Assembly Biosciences, down from $11.9 million in the prior quarter.
  • Over the last five years, Long-Term Investments for ASMB hit a ceiling of $28.0 million in Q4 2021 and a floor of $2.2 million in Q2 2018.
  • Median Long-Term Investments over the past 3 years was $11.8 million (2022), compared with a mean of $14.4 million.
  • Biggest five-year swings in Long-Term Investments: decreased 26.75% in 2018 and later plummeted 58.02% in 2022.
  • Assembly Biosciences' Long-Term Investments stood at $2.2 million in 2018, then soared by 1169.09% to $28.0 million in 2021, then plummeted by 58.02% to $11.7 million in 2022.
  • The last three reported values for Long-Term Investments were $11.7 million (Q4 2022), $11.9 million (Q2 2022), and $23.5 million (Q1 2022) per Business Quant data.